Surrozen (SRZN) Net Cash Flow Growth (3y) (2023 - 2026)
Surrozen (SRZN) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Surrozen |
239,016.67 |
-106.67 Mn |
- |
78.25% |
| Date | Value |
|---|
| Mar 31, 2026 |
78.25% |
| Dec 31, 2025 |
128.29% |
| Sep 30, 2025 |
-44.87% |
| Jun 30, 2025 |
-85.14% |
| Mar 31, 2025 |
77.21% |
| Dec 31, 2024 |
28.62% |
| Sep 30, 2024 |
-29.26% |
| Jun 30, 2024 |
62.49% |
| Mar 31, 2024 |
9.06% |
| Dec 31, 2023 |
33.35% |
